Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of CrystalGenomics patents

List of CrystalGenomics patents

List of SPI Lasers patents

List of Iron Mountain (company) patents

List of Cordis patents

List of companies in InsurTech Gateway's investment portfolio

Companies in the Water reuse industry

Patents where

Current Assignee

Name

is

CrystalGenomics

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 9758508 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same	Patent 9758508 was granted and assigned to CrystalGenomics on September, 2017 by the United States Patent and Trademark Office.	CrystalGenomics	CrystalGenomics		United States Patent and Trademark Office	9758508	September 12, 2017
	‌ US Patent 11602517 Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of pain		CrystalGenomics	CrystalGenomics		United States Patent and Trademark Office	11602517	March 14, 2023
	‌ US Patent 10413520 Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability	Patent 10413520 was granted and assigned to CrystalGenomics on September, 2019 by the United States Patent and Trademark Office.	CrystalGenomics	CrystalGenomics		United States Patent and Trademark Office	10413520	September 17, 2019
	‌ US Patent 7973060 Fab I inhibitor and process for preparing same	Patent 7973060 was granted and assigned to CrystalGenomics on July, 2011 by the United States Patent and Trademark Office.		CrystalGenomics		United States Patent and Trademark Office	7973060	July 5, 2011
	‌ US Patent 11230539 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same	Patent 11230539 was granted and assigned to CrystalGenomics on January, 2022 by the United States Patent and Trademark Office.	CrystalGenomics	CrystalGenomics		United States Patent and Trademark Office	11230539	January 25, 2022
	‌ US Patent 10604508 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same	Patent 10604508 was granted and assigned to CrystalGenomics on March, 2020 by the United States Patent and Trademark Office.	CrystalGenomics	CrystalGenomics		United States Patent and Trademark Office	10604508	March 31, 2020

6 results

0 selected

6 results

0 selected